neoag
Neoantigen × AI
Daily research signal
Brief · 2026-06-03

Nous-209 Targets Early Lynch Syndrome Mutations

The neoantigen vaccine landscape faces a critical inflection point: while market projections remain robust, recent clinical data and mechanistic reviews highlight persistent barriers in predictive accuracy, manufacturing speed, and tumor microenvironment resistance.

Key developments include early-stage validation of preventive vaccines for Lynch syndrome and new insights into HLA micropolymorphisms that constrain TCR selectivity, underscoring the need for precision in antigen selection over broad pipeline optimization.

15 items9 Clinical1 Commercial5 AI & Methods
Clinical09
01
Clinical

Personalized neoantigen cancer vaccines: Why clinical benefit remains inconsistent.

A critical review identifies structural barriers limiting consistent clinical benefit in personalized neoantigen vaccines, including limited predictive accuracy of selection pipelines and prolonged manufacturing timelines that allow tumor evolution. The authors argue that AI serves as an incremental optimizer rather than a transformative solution, emphasizing the need to address immunosuppressive microenvironments and validate biomarkers for patient stratification.

europepmc · 2026-04-12 · Singh S, Banerjee M, Kushwah AS.
02
Clinical

Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.

Molecular characterization of precancerous lesions in Lynch syndrome carriers confirms that Nous-209 target mutations occur early in adenoma progression, supporting the vaccine's preventive potential. The study found that Nous-209 mutation counts correlate strongly with microsatellite instability status, with dMMR/MSI-H lesions harboring the highest burden, validating the target population for this NCI-sponsored Phase Ib/II trial.

europepmc · 2026-06-01 · Micarelli E, De Marco L, Spaggiari P, D'Alise AM, Dal Buono A, Menini M, Giatti V, D'Apran
03
Clinical

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Dana-Farber Cancer Institute is conducting a Phase I trial evaluating NeoVax (personalized neoantigen peptides + poly-ICLC) combined with CDX-301 and either Nivolumab or Pembrolizumab for melanoma. The study is currently active but not recruiting, testing the combination of a personalized vaccine platform with checkpoint inhibitors and a novel adjuvant.

clinicaltrials · 2026-03-25 · Dana-Farber Cancer Institute
04
Clinical

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Ann & Robert H Lurie Children's Hospital of Chicago is recruiting for a Phase I trial of rHSC-DIPGVax, an off-the-shelf neoantigen heat shock protein vaccine containing 16 peptides, combined with BALSTILIMAB and ZALIFRELIMAB. The trial targets newly diagnosed DIPG and DMG patients who have completed radiation, aiming to assess safety and tolerability of this non-personalized approach.

clinicaltrials · 2026-03-17 · Ann & Robert H Lurie Children's Hospital of Chicago
05
Clinical

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

The NCI is running a Phase Ib/II trial of the Nous-209 vaccine in Lynch syndrome patients to evaluate safety, immune response, and potential effects on polyp or tumor development. The vaccine consists of man-made copies of neoantigens generated by mismatch repair errors, targeting the high-risk colorectal cancer population associated with inherited genetic variants.

clinicaltrials · 2026-03-03 · National Cancer Institute (NCI)
06
Clinical

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

Jia Wei is leading a Phase I trial assessing the safety and preliminary efficacy of XH001 injection combined with neoantigen vaccine-induced tumor-specific T-cell injection in advanced gastric cancer. The study aims to determine if this combined cellular and vaccine approach can shrink tumors and prolong survival in adult patients.

clinicaltrials · 2026-02-25 · Jia Wei
07
Clinical

Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

Beijing GoBroad Hospital is recruiting for a Phase I trial of XH001 injection combined with neoantigen vaccine-induced tumor-specific T-cell injection for advanced gastrointestinal cancer. The primary endpoints include safety, tolerance, and preliminary efficacy metrics such as tumor shrinkage and survival prolongation.

clinicaltrials · 2026-02-12 · Beijing GoBroad Hospital
08
Clinical

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Patrick Ott, MD, PhD is conducting a Phase I study of a personalized NeoAntigen Cancer Vaccine combined with Poly-ICLC and Ipilimumab for renal cell carcinoma. The trial is active but not recruiting, focusing on the safety and immunogenicity of this personalized vaccine platform in kidney cancer.

clinicaltrials · 2026-02-03 · Patrick Ott, MD, PhD
09
Clinical

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 <sup>+</sup> T cell responses and therapeutic protection in mouse tumor models.

Preclinical data demonstrates that a DNA prime and peptide boost immunization strategy elicits robust neoantigen-specific CD8+ T-cell responses and therapeutic protection in mouse tumor models. This regimen eliminated tumors in therapeutic settings and may be enhanced by combining with anti-PD-1 antibodies, offering a potential manufacturing and efficacy optimization for future vaccine platforms.

europepmc · 2026-01-11 · Morgado-Cáceres P, Hofmann-Vega F, Figueroa D, Saavedra-Almarza J, Gálvez-Cancino F, Díaz
Commercial01
01
Commercial

Neoantigen Cancer Vaccine Market to Reach USD 1.38 Billion by 2032, Growing at 14.9% CAGR on the Back of Precision-Engineered Immunotherapy Revolution: AnalystView Market Insights - GlobeNewswire

AnalystView Market Insights projects the neoantigen cancer vaccine market will reach USD 1.38 billion by 2032, growing at a 14.9% CAGR. This growth is attributed to the precision-engineered immunotherapy revolution, signaling continued investor and industry interest despite current clinical translation challenges.

news · 2026-02-03 · GlobeNewswire
AI & Methods05
01
AI / Methods

HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity.

Research reveals that HLA micropolymorphisms confine neoantigen conformational adaptability, directly guiding T cell receptor selectivity. Specifically, micropolymorphisms in HLA-A*03:02 versus A*03:01 prevent TCR binding by altering the neoantigen's conformational ensemble rather than peptide binding, highlighting a critical mechanistic constraint for vaccine design that must be accounted for in antigen selection pipelines.

europepmc · 2026-06-01 · Ma J, Ayres CM, Brambley CA, Eldaly B, Perera WWJG, Lazar JA, Kovrigin EL, Chandran SS, Kl
02
AI / Methods

Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy - Frontiers

A mechanistic and clinical review in Frontiers examines personalized melanoma immunotherapy, focusing on the biological rationale and translational challenges of neoantigen-based vaccines. The review contextualizes current clinical outcomes within the broader landscape of precision immunotherapy, addressing both the promise and limitations of targeting tumor-specific mutations.

news · 2026-03-12 · Frontiers
03
AI / Methods

Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types - Frontiers

Frontiers research indicates that tumor mutational burden can predict neoantigen profiles and immunotherapy response in microsatellite stable tumors across various cancer types. This finding suggests that TMB may serve as a broader predictive biomarker beyond MSI-H status, potentially expanding the addressable population for neoantigen-targeted therapies.

news · 2026-01-07 · Frontiers
05
AI / Methods

mRNA vaccines in gastrointestinal cancers: Mechanistic basis, translational challenges, and emerging therapeutic strategies.

A review of mRNA vaccines in gastrointestinal cancers highlights their rapid, cell-free manufacturing and modular design as key advantages over conventional platforms. However, efficacy is constrained by tumor heterogeneity and immunosuppressive microenvironments, with antigen selection strategies for personalized neoantigens remaining a critical variable for immune specificity and therapeutic variability.

europepmc · 2026-05-01 · Saha S, Chakraborty S, Nayak A.
Briefing stats
Clinical60%Commercial7%AI & Methods33%
Explore the fieldPrimerTrialsAnalysis